Celldex Therapeutics, Inc.
DE ˙ DB ˙ US15117B2025
25,28 € ↑0,78 (3,18%)
2026-06-04
AKTIENPREIS
SecurityDE:TCE2 / Celldex Therapeutics, Inc.
InstitutionInvesco Ltd.
Latest Disclosed Ownership93,684 shares
Latest Disclosed Value $ 2,971,657
Invesco Ltd. reports 3.93% increase in ownership of TCE2 / Celldex Therapeutics, Inc.

On May 12, 2026 - Invesco Ltd. filed a 13F-HR form disclosing ownership of 93,684 shares of Celldex Therapeutics, Inc. (DE:TCE2) valued at $2,398,310 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 19, 2026 disclosing 90,144 shares of Celldex Therapeutics, Inc.. This represents a change in shares of 3.93% during the quarter. The current value of the position is $2,368,332 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 93,684 3,540 3.93 2,972 21.36 0.0005
2026-02-19 2025-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 90,144 11,258 14.27 2,448 20.00 0.0004
2025-11-13 2025-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 78,886 16,000 25.44 2,041 59.50 0.0003
2025-08-13 2025-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 62,886 10,443 19.91 1,280 34.49 0.0002
2025-05-12 2025-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 52,443 10,342 24.56 952 -10.54 0.0002
2025-02-13 2024-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 42,101 871 2.11 1,064 -24.13 0.0002
2024-11-12 2024-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 41,230 97 0.24 1,401 -7.95 0.0003
2024-08-13 2024-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 41,133 -173,215 -80.81 1,522 -83.08 0.0003
2024-05-14 2024-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 214,348 -43,215 -16.78 8,996 -11.92 0.0019
2024-02-13 2023-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 257,563 220,428 593.59 10,215 900.39 0.0024
2023-11-13 2023-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 37,135 8,225 28.45 1,022 4.18 0.0003
2023-08-11 2023-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 28,910 -66,246 -69.62 981 -71.37 0.0003
2023-05-12 2023-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 95,156 18,674 24.42 3,424 0.44 0.0010
2023-02-13 2022-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 76,482 59,505 350.50 3,409 614.47 0.0010
2022-11-14 2022-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 16,977 -2,997 -15.00 477 -11.50 0.0002
2022-08-15 2022-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 19,974 1,851 10.21 539 -12.50 0.0002
2022-05-16 2022-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 18,123 -189,549 -91.27 616 -92.32 0.0002
2022-02-14 2021-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 207,672 -326,313 -61.11 8,025 -72.16 0.0019
2021-11-15 2021-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 533,985 103,578 24.07 28,830 100.32 0.0073
2021-08-17 2021-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 430,407 169,912 65.23 14,392 168.21 0.0035
2021-05-17 2021-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 260,495 260,495 5,366 0.0014
2021-02-16 2020-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 0 -534,584 -100.00 0 -100.00
2020-11-16 2020-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 534,584 534,584 7,928 0.0027
2020-05-15 2020-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 0 -39,394 -100.00 0 -100.00
2020-02-14 2019-12-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 39,394 -2,603 -6.20 88 -1.12 0.0000
2019-11-14 2019-09-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 41,997 -1,644 -3.77 89 -23.93 0.0000
2019-08-14 2019-06-30 13F/A-1 CELLDEX THERAPEUTICS INC COM NEW 15117B202 43,641 -1,507 -3.34 117 -47.30 0.0000
2019-08-14 2019-06-30 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 43,641 -1,507 117
2019-05-15 2019-03-31 13F CELLDEX THERAPEUTICS INC COM NEW 15117B202 45,148 -128,024 -73.93 222 552.94 0.0001
2019-02-14 2018-12-31 13F CELLDEX THERAPEUTICS INC COM 15117B103 173,172 18,257 11.79 34 -51.43 0.0000
2018-11-14 2018-09-30 13F CELLDEX THERAPEUTICS INC COM 15117B103 154,915 29,405 23.43 70 11.11 0.0000
2018-08-14 2018-06-30 13F CELLDEX THERAPEUTICS INC COM 15117B103 125,510 -93,715 -42.75 63 -87.67 0.0000
2018-05-15 2018-03-31 13F CELLDEX THERAPEUTICS INC COM 15117B103 219,225 44,472 25.45 511 3.02 0.0002
2018-02-14 2017-12-31 13F CELLDEX THERAPEUTICS INC COM 15117B103 174,753 -111 -0.06 496 -0.80 0.0002
2017-11-14 2017-09-30 13F CELLDEX THERAPEUTICS INC COM 15117B103 174,864 3,248 1.89 500 17.92 0.0002
2017-08-14 2017-06-30 13F CELLDEX THERAPEUTICS INC COM 15117B103 171,616 98,554 134.89 424 60.61 0.0001
2017-05-15 2017-03-31 13F CELLDEX THERAPEUTICS INC COM 15117B103 73,062 45,508 165.16 264 169.39 0.0001
2017-02-14 2016-12-31 13F CELLDEX THERAPEUTICS INC COM 15117B103 27,554 152 0.55 98 -11.71 0.0000
2016-11-14 2016-09-30 13F CELLDEX THERAPEUTICS INC COM 15117B103 27,402 -30,381 -52.58 111 -56.13 0.0000
2016-08-15 2016-06-30 13F CELLDEX THERAPEUTICS INC COM 15117B103 57,783 -6,033 -9.45 253 4.55 0.0001
2016-05-16 2016-03-31 13F CELLDEX THERAPEUTICS INC COM 15117B103 63,816 -629,303 -90.79 242 -97.77 0.0001
2016-02-16 2015-12-31 13F CELLDEX THERAPEUTICS INC COM 15117B103 693,119 81,389 13.30 10,868 68.57 0.0043
2015-11-16 2015-09-30 13F CELLDEX THERAPEUTICS INC COM 15117B103 611,730 29,515 5.07 6,447 -56.09 0.0027
2015-08-14 2015-06-30 13F CELLDEX THERAPEUTICS COMMON 15117B103 582,215 -179,491 -23.56 14,683 -30.84 0.0058
2015-05-15 2015-03-31 13F CELLDEX THERAPEUTICS COMMON 15117B103 761,706 206,030 37.08 21,229 109.34 0.0082
2015-02-13 2014-12-31 13F CELLDEX THERAPEUTICS COMMON 15117B103 555,676 0 0.00 10,141 40.81 0.0039
2014-11-14 2014-09-30 13F CELLDEX THERAPEUTICS COMMON 15117B103 555,676 -99,870 -15.23 7,202 -32.69 0.0029
2014-08-14 2014-06-30 13F CELLDEX THERAPEUTICS COMMON 15117B103 655,546 -5,221 -0.79 10,699 -8.37 0.0042
2014-05-15 2014-03-31 13F CELLDEX THERAPEUTICS COMMON 15117B103 660,767 -49,420 -6.96 11,676 -32.09 0.0047
2014-02-13 2013-12-31 13F CELLDEX THERAPEUTICS COMMON 15117B103 710,187 232,281 48.60 17,193 1.54 0.0068
2013-11-13 2013-09-30 13F CELLDEX THERAPEUTICS COMMON 15117B103 477,906 432,944 962.91 16,932 2,311.97 0.0074
2013-08-14 2013-06-30 13F CELLDEX THERAPEUTICS COMMON 15117B103 44,962 44,962 702 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.